Acrivon Therapeutics, Inc.
ACRV
$2.57
$0.041.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.20% | -24.57% | -30.62% | -33.40% | -53.75% |
| Total Depreciation and Amortization | 52.35% | 63.49% | 72.13% | 87.69% | 66.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.71% | 22.85% | 17.09% | 26.12% | 40.21% |
| Change in Net Operating Assets | -104.72% | -88.34% | -49.43% | -70.04% | 113.11% |
| Cash from Operations | -8.43% | -33.24% | -40.84% | -54.00% | -53.11% |
| Capital Expenditure | 26.36% | -12.55% | 3.22% | -114.91% | -696.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 243.97% | 223.12% | -173.80% | -194.23% | 34.02% |
| Cash from Investing | 229.23% | 214.87% | -181.30% | -202.08% | 29.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | 8,097.78% | 8,943.48% | -32.89% |
| Repurchase of Common Stock | 61.99% | -15.81% | -84.42% | -94.29% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -100.58% | 4,893.64% | 5,280.23% | 2,118.01% |
| Cash from Financing | -101.01% | -102.14% | 7,102.09% | 7,888.10% | 16.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.00% | -154.51% | 602.21% | -45.00% | 706.96% |